BOSTON—Amy Elazzouzi, Vice President of Finance at Aura Biosciences , Inc. (NASDAQ:AURA), not too long ago offered 1,001 shares of the corporate’s widespread inventory. The shares had been offered at a weighted common value of $7.6715, totaling roughly $7,679. The transaction comes as AURA trades at $7.93, with analysts setting a mean value goal of $20-23, suggesting vital upside potential in keeping with InvestingPro knowledge. This transaction was executed to cowl tax withholding obligations associated to the vesting of restricted inventory models. Following this sale, Elazzouzi holds 38,442 shares instantly. The sale was performed mechanically, not at Elazzouzi’s discretion, as a part of a pre-arranged plan. Aura Biosciences, a Boston-based biotechnology firm valued at $388 million, maintains a powerful liquidity place with a present ratio of 12.47 and more money than debt on its steadiness sheet. InvestingPro evaluation reveals 6 extra key insights about AURA’s monetary well being and development prospects.
This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.
Quintessentially, the luxurious concierge service based by the Queen's nephew, is in talks to discover…
A music video-streaming service whose shareholders embody the U2 bassist Adam Clayton will this week…
Wherever you might be once you purchase a pint can have a huge impact on…
The Italian-owned producer of a few of Britain's hottest meals manufacturers has employed bankers to…
The King's private fortune has shot up by £30m to place him on par with…
Adele, the Grammy award-winning artist, has joined the record of music superstars investing in Audoo,…